Does OCRELIZUMAB Cause Tonsillar hypertrophy? 8 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 8 reports of Tonsillar hypertrophy have been filed in association with OCRELIZUMAB (OCREVUS). This represents 0.0% of all adverse event reports for OCRELIZUMAB.
8
Reports of Tonsillar hypertrophy with OCRELIZUMAB
0.0%
of all OCRELIZUMAB reports
0
Deaths
2
Hospitalizations
How Dangerous Is Tonsillar hypertrophy From OCRELIZUMAB?
Of the 8 reports, 2 (25.0%) required hospitalization.
Is Tonsillar hypertrophy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OCRELIZUMAB. However, 8 reports have been filed with the FAERS database.
What Other Side Effects Does OCRELIZUMAB Cause?
Covid-19 (11,454)
Fatigue (5,704)
Urinary tract infection (3,618)
Headache (3,036)
Multiple sclerosis (2,609)
Asthenia (2,509)
Nasopharyngitis (2,479)
Gait disturbance (2,384)
Pneumonia (2,333)
Pain (2,327)
What Other Drugs Cause Tonsillar hypertrophy?
ADALIMUMAB (151)
ONDANSETRON (51)
SOMATROPIN (43)
SECUKINUMAB (42)
DUPILUMAB (39)
METHOTREXATE (39)
INFLIXIMAB (31)
TACROLIMUS (26)
INFLIXIMAB-DYYB (25)
ETANERCEPT (24)
Which OCRELIZUMAB Alternatives Have Lower Tonsillar hypertrophy Risk?
OCRELIZUMAB vs OCRIPLASMIN
OCRELIZUMAB vs OCTINOXATE\OCTISALATE\ZINC
OCRELIZUMAB vs OCTINOXATE\OCTOCRYLENE
OCRELIZUMAB vs OCTREOTIDE
OCRELIZUMAB vs OCTREOTIDE\OCTREOTIDE